Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM) Read more about Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM)
Supernus Announces First Quarter 2014 Results Read more about Supernus Announces First Quarter 2014 Results
Supernus to Host First Quarter 2014 Earnings Conference Call Read more about Supernus to Host First Quarter 2014 Earnings Conference Call
Supernus Announces Fourth Quarter and Full Year 2013 Results Read more about Supernus Announces Fourth Quarter and Full Year 2013 Results
Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™ Read more about Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™
Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call Read more about Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call
Supernus to Present at Cowen and Company Healthcare Conference in March Read more about Supernus to Present at Cowen and Company Healthcare Conference in March
Supernus at Citibank and RBC Global Healthcare Conferences in February Read more about Supernus at Citibank and RBC Global Healthcare Conferences in February
Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR® Read more about Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR®
Supernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product Read more about Supernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product